| Mold infections of the central nervous system M McCarthy, A Rosengart, AN Schuetz, DP Kontoyiannis, TJ Walsh New England Journal of Medicine 371 (2), 150-160, 2014 | 217 | 2014 |
| Novel agents and drug targets to meet the challenges of resistant fungi MW McCarthy, DP Kontoyiannis, OA Cornely, JR Perfect, TJ Walsh The Journal of infectious diseases 216 (suppl_3), S474-S483, 2017 | 182 | 2017 |
| In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms A Katragkou, M McCarthy, EL Alexander, C Antachopoulos, J Meletiadis, ... Journal of Antimicrobial Chemotherapy 70 (2), 470-478, 2015 | 129 | 2015 |
| Transgender patients, hospitalists, and ethical care MW McCarthy, E Reis, JJ Fins Perspectives in Biology and Medicine 59 (2), 234-245, 2016 | 118 | 2016 |
| Novel applications for serum procalcitonin testing in clinical practice JJ Choi, MW McCarthy Expert review of molecular diagnostics 18 (1), 27-34, 2018 | 85 | 2018 |
| Cefiderocol: a novel siderophore cephalosporin JJ Choi, MW McCarthy Expert opinion on investigational drugs 27 (2), 193-197, 2018 | 79 | 2018 |
| Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial S Naggie, DR Boulware, CJ Lindsell, TG Stewart, N Gentile, S Collins, ... Jama 328 (16), 1595-1603, 2022 | 70 | 2022 |
| Recent advances in the treatment of scedosporiosis and fusariosis MW McCarthy, A Katragkou, E Iosifidis, E Roilides, TJ Walsh Journal of Fungi 4 (2), 73, 2018 | 60 | 2018 |
| Emerging drugs and vaccines for candidemia B Moriyama, LA Gordon, M McCarthy, SA Henning, TJ Walsh, SR Penzak Mycoses 57 (12), 718-733, 2014 | 49 | 2014 |
| Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial S Naggie, DR Boulware, CJ Lindsell, TG Stewart, AJ Slandzicki, SC Lim, ... JAMA 329 (11), 888-897, 2023 | 48 | 2023 |
| Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial MW McCarthy, S Naggie, DR Boulware, CJ Lindsell, TG Stewart, ... JAMA 329 (4), 296-305, 2023 | 48 | 2023 |
| Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia: a randomized clinical trial JA O’Halloran, ER Ko, KJ Anstrom, E Kedar, MW McCarthy, RA Panettieri, ... Jama 330 (4), 328-339, 2023 | 47* | 2023 |
| PCR methodology and applications for the detection of human fungal pathogens MW McCarthy, TJ Walsh Expert Review of Molecular Diagnostics 16 (9), 1025-1036, 2016 | 46 | 2016 |
| The care of the ultra-orthodox Jewish patient E Gabbay, MW McCarthy, JJ Fins Journal of religion and health 56, 545-560, 2017 | 43 | 2017 |
| Fungal infections of the central nervous system in children MW McCarthy, D Kalasauskas, V Petraitis, R Petraitiene, TJ Walsh Journal of the Pediatric Infectious Diseases Society 6 (3), e123-e133, 2017 | 42 | 2017 |
| In Vitro Combination of Isavuconazole with Micafungin or Amphotericin B Deoxycholate against Medically Important Molds A Katragkou, M McCarthy, J Meletiadis, V Petraitis, PW Moradi, ... Antimicrobial agents and chemotherapy 58 (11), 6934-6937, 2014 | 42 | 2014 |
| Therapeutic strategies to address monkeypox MW McCarthy Expert Review of Anti-infective Therapy 20 (10), 1249-1252, 2022 | 41 | 2022 |
| Drug development challenges and strategies to address emerging and resistant fungal pathogens MW McCarthy, TJ Walsh Expert review of anti-infective therapy 15 (6), 577-584, 2017 | 41 | 2017 |
| Clinical pharmacokinetics and pharmacodynamics of isavuconazole MW McCarthy, B Moriyama, R Petraitiene, TJ Walsh, V Petraitis Clinical pharmacokinetics 57, 1483-1491, 2018 | 38 | 2018 |
| Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial MW McCarthy, KR Keyloun, P Gillard, JJ Choi, N Pickell, R Copp, ... Infectious Diseases and Therapy 9, 53-67, 2020 | 34 | 2020 |
